Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
7.830
+0.470 (+6.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Sage Therapeutics to Present at Upcoming August Investor Conferences
August 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Where Sage Therapeutics Stands With Analysts
July 11, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
8 Analysts Have This to Say About Sage Therapeutics
May 24, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
Sage Therapeutics to Present at Upcoming June Investor Conferences
June 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
June 01, 2022
Sage and Biogen say their MDD drug met every goal in a study of postpartum women.
Via
Investor's Business Daily
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
June 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Analyst Ratings for Sage Therapeutics
May 04, 2022
Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Sage Therapeutics: Q1 Earnings Insights
May 03, 2022
Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings For Sage Therapeutics
March 31, 2022
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
May 03, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For May 3, 2022
May 03, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Via
Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
May 02, 2022
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
May 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 21, 2022
Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
April 01, 2022
Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday!
Via
InvestorPlace
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
April 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at 2022 Stifel CNS Days
March 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
March 31, 2022
Upgrades
Via
Benzinga
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
March 15, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Expert Ratings For Sage Therapeutics
February 25, 2022
Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
February 24, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.